Management of Carfilzomib-Associated Cardiac Adverse Events

Joseph R Mikhael

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2016

Fingerprint

Multiple Myeloma
Proteasome Inhibitors
Proxy
Dexamethasone
Therapeutics
carfilzomib
lenalidomide
Clinical Studies

Keywords

  • Cardiopulmonary
  • Clinical trials
  • Multiple myeloma
  • Proteasome inhibitor
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Management of Carfilzomib-Associated Cardiac Adverse Events. / Mikhael, Joseph R.

In: Clinical Lymphoma, Myeloma and Leukemia, 2016.

Research output: Contribution to journalArticle

@article{9b46796306154675aab59c4cf623e954,
title = "Management of Carfilzomib-Associated Cardiac Adverse Events",
abstract = "Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.",
keywords = "Cardiopulmonary, Clinical trials, Multiple myeloma, Proteasome inhibitor, Review",
author = "Mikhael, {Joseph R}",
year = "2016",
doi = "10.1016/j.clml.2016.01.008",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Management of Carfilzomib-Associated Cardiac Adverse Events

AU - Mikhael, Joseph R

PY - 2016

Y1 - 2016

N2 - Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.

AB - Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.

KW - Cardiopulmonary

KW - Clinical trials

KW - Multiple myeloma

KW - Proteasome inhibitor

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84958554606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958554606&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2016.01.008

DO - 10.1016/j.clml.2016.01.008

M3 - Article

C2 - 26907720

AN - SCOPUS:84958554606

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -